drugset
drugset / Trial / NCT04987996

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

NCT04987996 ↗

Phase 2 Withdrawn Providence Health & Services Providence Cancer Center, Earle A. Chiles Research Institute · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the safety \& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.

Timeline

Start
2023-07-01
Primary completion
2027-07-01
Completion
2031-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject belapectin Other / unclassified 4 mg/kg Intravenous

Indications

head and neck squamous cell carcinoma metastatic melanoma